Founded with a mission to revolutionize the treatment of chronic infections, SciBac leverages its patented MERGE platform to develop biotherapeutics that enhance beneficial microorganisms. The company's core focus is on treating antibiotic-resistant diseases, particularly chronic infections associated with cystic fibrosis. SciBac's innovative approach employs directed evolution to increase the therapeutic efficacy of its products, targeting pathogens such as Pseudomonas, Staph, Burkholderia, and NTM.
SciBac has garnered attention for its cutting-edge technology and impactful solutions in the biotherapeutics space. The company has received investments from notable venture capital firms and has formed strategic partnerships with leading research institutions. Key achievements include the development of its first two therapeutics specifically designed for cystic fibrosis-related infections. SciBac's work has the potential to significantly improve patient outcomes and address critical gaps in the treatment of antibiotic-resistant infections.
